Guard Therapeutics International AB (Nasdaq First North Growth Market Stockholm: GUARD) has been placed under observation status and faces potential delisting on June 17, 2026, unless it completes a merger, reverse acquisition, or submits a new listing application. If no transaction is reached, the board intends to recommend voluntary liquidation with funds distributed to shareholder.

Guard Therapeutics International AB (publ), a Swedish clinical-stage biotechnology company listed on Nasdaq First North Growth Market Stockholm, has announced that it has been informed by Nasdaq that the company currently does not fulfil the ongoing listing requirement regarding active operations. In a press release issued on April 9, 2026, the company disclosed that Nasdaq may delist the Company's financial instruments on June 17, 2026, provided that the Company has not, prior to that date, communicated concrete measures for how the operational requirement will be fulfilled or, alternatively, submitted a complete listing application in the event the Company pursues far-reaching changes that would require a new listing review. The announcement places Guard Therapeutics at a critical juncture and reflects the company's ongoing evaluation of potential strategic alternatives, including merger transactions, reverse acquisitions, and potential voluntary liquidation with distribution of available liquid funds to shareholders if no suitable transaction is identified within the required timeframe.

About Guard Therapeutics

Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with significant unmet medical need, focusing particularly on different forms of kidney disease. The company's candidate drugs are based on the endogenous protein alpha-1-microglobulin (A1M), which has been the subject of scientific research and therapeutic development efforts aimed at leveraging its biological properties to address conditions affecting the kidneys. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm under the ticker GUARD, and its Certified Adviser is Redeye Nordic Growth AB. The company is led by Chief Executive Officer Tobias Agervald and is headquartered at Box 5216, SE-102 45 Stockholm. Like many clinical-stage biotechnology companies, Guard Therapeutics has faced the challenges of developing and advancing therapeutic candidates through the drug development process, which typically requires significant time, capital, and scientific expertise before a product can reach commercial markets.

Ongoing Listing Requirement on Nasdaq First North Growth Market

Nasdaq First North Growth Market is a Nordic multilateral trading facility (MTF) operated by Nasdaq and designed to provide growth-oriented companies with access to public capital markets. Companies listed on the market are subject to various ongoing listing requirements designed to ensure that investors have adequate information and protection. One such requirement relates to active operations, which generally means that the listed company must be engaged in meaningful commercial activities consistent with its stated business purpose. A company that does not have active operations risks no longer meeting the listing criteria, and in such cases Nasdaq may initiate a delisting process. The application of the active operations requirement to Guard Therapeutics reflects the specific circumstances of the company and the determination by Nasdaq that its current activities may not meet this requirement. The company now has a defined timeframe within which it must either demonstrate that it will fulfil the requirement or pursue an alternative path forward.

Strategic Alternatives Under Evaluation

According to the press release, Guard Therapeutics is currently evaluating potential counterparties for a merger transaction or, alternatively, a reverse acquisition. A reverse acquisition, sometimes referred to as a reverse takeover, is a transaction in which a private company effectively becomes listed by merging with or being acquired by an existing listed company, taking advantage of the listed entity's public market status. This approach can be attractive to private companies seeking an alternative route to a public listing without the time and cost of a traditional initial public offering. For Guard Therapeutics, pursuing such a transaction would provide a new business combination partner whose operations would satisfy the active operations requirement, thereby preserving the listing for the combined entity. The company's primary focus is that the structure for a potential transaction can be presented during the second quarter of 2026, which would allow Nasdaq to reassess the operational requirement prior to the June 17 deadline and potentially remove the immediate risk of delisting.

Potential Delisting and Voluntary Liquidation

The company has been transparent about the possibility that the ongoing evaluation of strategic alternatives may not result in a transaction or other strategic outcome within the required period. In such a scenario, the Board of Directors intends to recommend delisting from Nasdaq First North Growth Market and voluntary liquidation of the company, with available liquid funds distributed to shareholders. This contingency plan provides shareholders with a clear understanding of the possible outcomes and the board's intended approach if no transaction can be completed. Any decision regarding a merger, reverse acquisition, delisting, or voluntary liquidation would be subject to shareholder approval at a future general meeting, ensuring that the ultimate direction of the company is determined by its owners. Guard Therapeutics has stated that it undertakes no obligation to provide further information until the Board of Directors has made final decisions, subject to applicable rules and regulations governing listed companies and the disclosure of material information to the market.

Biotechnology Industry Context

The biotechnology industry is characterized by high risk and high reward, with only a small percentage of drug candidates successfully navigating the long and costly drug development process from initial discovery through clinical trials, regulatory approval, and commercial launch. Many clinical-stage companies rely heavily on capital markets funding to support their research and development activities, and the availability of such funding can vary significantly over time based on broader market conditions, investor sentiment, and the specific progress of individual companies and their product candidates. Companies that encounter difficulties in their development programs, experience adverse clinical trial results, or are unable to raise sufficient capital may face significant challenges in maintaining their operations. In such situations, strategic alternatives such as mergers, acquisitions, reverse takeovers, or voluntary liquidation become important considerations for boards of directors seeking to maximize value for shareholders within the constraints of their specific circumstances.

Kidney Disease and Unmet Medical Need

Kidney disease represents a significant global health challenge, affecting millions of people worldwide and contributing to substantial morbidity and mortality. Chronic kidney disease, acute kidney injury, and other kidney-related conditions often lack effective treatment options, creating meaningful unmet medical need in this therapeutic area. Research into novel approaches to treating kidney disease continues to be an active field, with various companies pursuing different mechanisms, targets, and therapeutic modalities. Alpha-1-microglobulin (A1M), the endogenous protein on which Guard Therapeutics has based its candidate drugs, is one approach among several being investigated for potential clinical applications in kidney disease. Despite the importance of kidney disease as a therapeutic area and the scientific rationale behind various approaches, the path from preclinical research through clinical development to commercial success remains long and uncertain for any specific drug candidate or therapeutic approach in this field.

Observation Status and Investor Communications

The placement of a listed company in observation status by Nasdaq serves as a formal notification to the market that specific regulatory or listing concerns have been identified. Observation status does not in itself mean that the company will be delisted, but it does indicate that the exchange has concerns that must be addressed within a specified timeframe to avoid delisting. For investors, observation status is an important signal to carefully monitor developments at the company in question and to consider the implications for their investment positions. Guard Therapeutics' transparent communication about the observation status and the potential outcomes—including either a successful strategic transaction or delisting and voluntary liquidation—reflects good practice in investor communications. Providing shareholders with clear information about the range of possible scenarios enables them to make informed decisions and understand the risks and opportunities facing the company during this critical period leading up to the June 17, 2026 deadline.

Reverse Acquisitions as a Strategic Tool

Reverse acquisitions have become a recognized tool in the corporate toolkit for companies seeking alternative paths to becoming or remaining publicly listed. The mechanism allows a private company to effectively go public by combining with an existing listed entity, inheriting its listing status and often its share capital structure. For the listed company in such a transaction, the reverse acquisition provides a new operating business that can satisfy ongoing listing requirements, while for the private company, it offers a faster and often less expensive route to public markets compared to a traditional initial public offering. Reverse acquisitions have been used in various industries and markets, and they can be particularly relevant for companies like Guard Therapeutics that face specific listing-related challenges. The success of such a transaction depends on finding a suitable counterparty, negotiating terms acceptable to both parties' stakeholders, obtaining any required regulatory approvals, and completing the transaction within the available timeframe before a listing-related deadline expires or requires separate action.

Shareholder Considerations

For current shareholders of Guard Therapeutics, the announcement of observation status and the potential paths forward present important considerations. If the company successfully identifies and completes a merger or reverse acquisition transaction, shareholders may receive shares in a combined entity with new operations and potentially different investment characteristics than the current company. Alternatively, if the company proceeds with delisting and voluntary liquidation, shareholders would receive a distribution of available liquid funds. The relative attractiveness of these alternatives depends on the specific terms of any transaction that might be negotiated and the amount of funds that could be distributed in a liquidation scenario. Shareholders are unlikely to have detailed information about either outcome until the Board of Directors has made final decisions and presented them to the market. Monitoring company communications and participating in any future general meetings where strategic decisions may be voted upon will be important for investors seeking to protect and manage their positions during this period of uncertainty.

Governance and Board Responsibilities

The Board of Directors of Guard Therapeutics bears significant responsibility for navigating the company through the current situation and making decisions that are in the best interests of shareholders as a whole. Board duties in such circumstances typically include carefully evaluating all available strategic alternatives, engaging with potential transaction counterparties, ensuring compliance with applicable regulations and listing requirements, communicating transparently with the market, and ultimately making recommendations to shareholders about the course of action to pursue. The board's statement that it intends to recommend delisting and voluntary liquidation if no transaction can be completed reflects a clear framework for decision-making and provides shareholders with visibility into the contingency plan. Boards facing these situations must balance the desire to maximize value with the need to make timely decisions, manage company resources prudently during the evaluation period, and respect the specific requirements imposed by the listing regime and the applicable corporate law framework.

Conclusion

Guard Therapeutics' April 9, 2026 announcement regarding its observation status on Nasdaq First North Growth Market and the June 17, 2026 delisting deadline marks a critical moment for the Swedish clinical-stage biotechnology company. With the Board of Directors actively evaluating merger and reverse acquisition opportunities, the company faces a tight timeline to identify a suitable strategic transaction that would satisfy Nasdaq's active operations requirement. If no such transaction can be completed, the board intends to recommend delisting and voluntary liquidation, with available funds distributed to shareholders. The outcome will ultimately depend on the availability of suitable transaction counterparties and the terms that can be negotiated during the evaluation period. For shareholders, analysts, and the broader Nordic biotechnology community, Guard Therapeutics' situation illustrates the challenges that clinical-stage companies can face when their development programs do not progress as initially planned and when specific listing requirements come into play in the public markets. required timeframe.